18th Nov 2020 20:22
Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm headquartered in London - Enters into convertible loan note financing facility with Mint Capital Ltd to which it has conditionally agreed to issue up to GBP60 million convertible unsecured loan notes to Mint Capital. Funds will allow Hemogenyx to accelerate and broaden development pipeline of novel therapies and treatments for blood cancers and viral diseases.
Current stock price: 9.28 pence
Year-to-date change: up sharply from 1.95p
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hemogenyx